Prospective, Multi-Center, Observational, Whole Blood Specimen Collection Study in Participants With Rheumatoid Arthritis With Inadequate Response or Intolerance to a DMARD Starting a New bDMARD or tsDMARD Treatment +/- csDMARD

NCT05936970 · tracked via the Priya Life Science USA tracker

Sponsor

Aqtual, Inc.

Phase

Observational

Started

2023-06-29

Last updated

2026-07-21

Condition(s) studied

Rheumatoid Arthritis

Study summary

The primary goal of this study is to assess a cfDNA-based blood test using genetic, transcriptomic and/or epigenetic information to help doctors predict the best treatment options for rheumatoid arthritis (RA) patients with inadequate response or intolerance to previous therapies.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Ability to understand and provide written informed consent. * Male or female ≥18 years of age at enrollment. * Diagnosis of Rheumatoid Arthritis at the time of enrollment. * Prior treatment with at least 1 csDMARD, bDMARD, or tsDMARD * Planning to initiate a new bDMARD (+/- csDMARD) or tsDMARD (+/- csDMARD), within 1 month after enrollment. * Moderate to high Clinical Disease Activity Index (CDAI) of (\>10) with a minimum 4 tender joints and 4 swollen joints at the time of screening. Exclusion Criteria: * Unsuitable for participation in the opinion of the principal investigator.

Primary outcome measure(s)

Clinical Response Prediction — Approximately 3 months
This study aims to identify cfDNA signatures that predict response to specific bDMARD or tsDMARD therapies for RA treatment.

Trial sites (42)

Facility	City	Region
Arizona Arthritis & Rheumatology Research	Phoenix	Arizona
Medvin Clinical Research - Apple Valley	Apple Valley	California
Medvin Clinical Research - Covina	Covina	California
Medvin Clinical Research - Riverside	Riverside	California
Medvin Clinical Research - Tujunga	Tujunga	California
Medvin Clinical Research - Whittier	Whittier	California
AARDS Research, Inc	Aventura	Florida
Highlands Advanced Rheumatology and Arthritis Center (HARAC)	Avon Park	Florida
Bay Area Rheumatology	Clearwater	Florida
Believe Clinical Trials	Coral Springs	Florida
GNP Research	Hollywood	Florida
Life Clinical Trials	Margate	Florida
Vitalia Medical Research	Palm Beach Gardens	Florida
Shine a Light Research	Sun City Center	Florida
West Broward Rheumatology Associates	Tamarac	Florida
St. Luke's Clinic	Boise	Idaho
Arnold Arthritis & Rheumatology	Skokie	Illinois
Illinois Bone and Joint Institute	Willowbrook	Illinois
Lake Cumberland Rheumatology	New Albany	Indiana
Clinical Research Institute of Michigan	Saint Clair Shores	Michigan
St. Paul Rheumatology	Eagan	Minnesota
AARA/Kansas City Physician Partners	Kansas City	Missouri
New England Rheumatology & Osteoporosis	Henniker	New Hampshire
Arthritis Rheumatism and Bone Disease Associates	Voorhees Township	New Jersey
Sahni Rheumatology & Therapy	West Long Branch	New Jersey
Albuquerque Center for Rheumatology	Albuquerque	New Mexico
Arthritis and Osteoporosis Consultants of the Carolinas	Charlotte	North Carolina
Cape Fear Arthritis Care	Leland	North Carolina
Triangle Arthritis & Rheumatology	Raleigh	North Carolina
Carolina Arthritis Associates	Wilmington	North Carolina
AARA/Rheumatic Diseases Clinic of Oklahoma	Oklahoma City	Oklahoma
Altoona Center for Clinical Research	Duncansville	Pennsylvania
Arthritis Group Rheumatology	Philadelphia	Pennsylvania
PA Regional Center for Arthritis and Osteoporosis Research	Philadelphia	Pennsylvania
Carolina Health Specialists/Trial Management Associates	Myrtle Beach	South Carolina
Accurate Clinical Management	Baytown	Texas
Rheumatology Care Center	Bellaire	Texas
AARA Clinical Research/Lone Star Arthritis and Rheumatology	Fort Worth	Texas
Accurate Clinical Research	Houston	Texas
Advanced Rheumatology of Houston	The Woodlands	Texas

+ 2 more sites — see the full list on the official registry below.

Other trials for the same condition

Ultrasound Neuroimmune Modulation in Adults With Rheumatoid Arthritis Recruiting

A Clinical Study to Assess the Efficacy of Cannabigerol in Patients with Active Rheumatoid Arthritis. Active, not recruiting

Post Market Clinical Follow-up (PMCF) Study of the A.L.P.S. Proximal Humerus Plating System Active, not recruiting

Study of GS-0151 in Participants With Rheumatoid Arthritis Active, not recruiting

A Study of Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Rheumatoid Arthritis (RENOIR) Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05936970 on ClinicalTrials.gov ↗ ← All trials in the USA